Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | S100A4 | P26447 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.41 |
| ▸ | ABAT | P80404 | 1/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29709767 | 1.00 | ERN1 (0.59) | ERN1ALDH1A1CYP3A4KDM4EMAPT | |
| Bromide SCHEMBL28468459 | 0.98 | ERN1 (0.57) | ERN1ALDH1A1CYP3A4KDM4EMAPT | |
| SCHEMBL6694236 | 0.89 | ALDH1A1 (0.61) | ERN1ALDH1A1CYP3A4KDM4EMAPT | |
| SCHEMBL203751 | 0.85 | ERN1 (0.59) | ERN1ALDH1A1CYP3A4KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL28075934 | 0.83 | ERN1 (0.57) | ERN1ALDH1A1CYP3A4KDM4EMAPT | |
| SCHEMBL16951741 | 0.83 | ERN1 (0.49) | ERN1ALDH1A1CYP3A4MAPTS100A4 | |
| SCHEMBL16951426 | 0.83 | ERN1 (0.45) | ERN1ALDH1A1CYP3A4MAPTS100A4 | |
| SCHEMBL5460251 | 0.82 | ERN1 (0.45) | ERN1ALDH1A1CYP3A4KDM4EMAPT | |
| SCHEMBL7287497 | 0.81 | MAPT (0.50) | ERN1ALDH1A1KDM4EMAPTVCAM1 | |
| SCHEMBL21812372 | 0.80 | ERN1 (0.46) | ERN1ALDH1A1CYP3A4KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 416 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120114456-A | Pyruvate-based composition for treating pneumonia and preparation method thereof | 江苏长泰药业股份有限公司 | 2025-06-10 | — | — | CN | claimed |
| CN-119684127-A | Method for preparing aromatic phenylpropionyl ketone by photoinduction and biological application | 华南理工大学 | 2025-03-25 | — | — | CN | claimed |
| CN-116102561-B | Amino coordination-based tricyclic quinazolinyl two-dimensional conductive metal organic framework material | 天津大学 | 2024-12-27 | — | — | CN | claimed |
| CN-117417867-A | Enterobacter cloacae (Enterobacter cloacae) ZJUT16 and application thereof | 浙江工业大学 | 2024-01-19 | — | — | CN | claimed |
| CN-117343948-A | Recombinant expression plasmid of nitroreductase EcNTR and application thereof | 浙江工业大学 | 2024-01-05 | — | — | CN | claimed |
| CN-116102561-A | Amino coordination-based tricyclic quinazolinyl two-dimensional conductive metal organic framework material | 天津大学 | 2023-05-12 | — | — | CN | claimed |
| CN-115835909-B | Cannabinoid receptor type 2 (CB 2) modulators and uses thereof | 泰昂治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122010905-A | Pyrazolyl derivatives as anticancer agents | 诺华股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-3856736-B1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4344702-B1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2026-01-28 | — | — | EP | disclosed |
| US-20250375526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4620470-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20040186115-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-09-23 | — | — | US | disclosed |
| WO-2004058749-A1 | BENZISOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040072359-A1 | Sensor for monitoring an analyte | JOHNS HOPKINS UNIVERSITY, THE | 2004-04-15 | — | — | US | disclosed |
| WO-2004027412-A1 | SENSOR FOR MONITORING AN ANALYTE | THE JOHNS HOPKINS UNIVERSITY (US) | 2004-04-01 | — | — | WO | disclosed |
| US-20020032262-A1 | 2-aminoarylmethylamine solid support templated for preparation of highly functionalized heterocycle compounds | ZHANG JINFANG (US) | 2002-03-14 | — | — | US | disclosed |
| US-4307232-A | Preparation of dialkyl- and diarylphosphonoalkanoic acids and substituted acrylic acids | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-12-22 | — | — | US | disclosed |
| US-4017313-A | Photosensitive composition containing a leuco dye, a photosensitizer, an aromatic aldehyde and a secondary or tertiary amine and the use thereof in a direct-print process | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ERN1 310/4885ALDH1A1 2776/4885CYP3A4 2542/4885 |
| US-20040186115-A1 | Compositions useful as inhibitors of protein kinases | PIM3, PIM1, JAK1 | ERN1 736/4885ALDH1A1 2778/4885CYP3A4 3152/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | ERN1 1382/4885ALDH1A1 100/4885CYP3A4 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.